Literature DB >> 34859135

Production of Recombinant Replication-defective Lentiviruses Bearing the SARS-CoV or SARS-CoV-2 Attachment Spike Glycoprotein and Their Application in Receptor Tropism and Neutralisation Assays.

Nazia Thakur1,2, Giulia Gallo1, Ahmed M E Elreafey1, Dalan Bailey1.   

Abstract

For enveloped viruses, such as SARS-CoV-2, transmission relies on the binding of viral glycoproteins to cellular receptors. Conventionally, this process is recapitulated in the lab by infection of cells with isolated live virus. However, such studies can be restricted due to the availability of high quantities of replication-competent virus, biosafety precautions and associated trained staff. Here, we present a protocol based on pseudotyping to produce recombinant replication-defective lentiviruses bearing the SARS-CoV or SARS-CoV-2 attachment Spike glycoprotein, allowing the investigation of viral entry in a lower-containment facility. Pseudoparticles are produced by cells transiently transfected with plasmids encoding retroviral RNA packaging signals and Gag-Pol proteins, for the reconstitution of lentiviral particles, and a plasmid coding for the viral attachment protein of interest. This approach allows the investigation of different aspects of viral entry, such as the identification of receptor tropism, the prediction of virus host range, and zoonotic transmission potential, as well as the characterisation of antibodies (sera or monoclonal antibodies) and pharmacological inhibitors that can block entry. Graphic abstract: SARS-CoV and SARS-CoV-2 pseudoparticle generation and applications. ©Copyright Thakur et al.

Entities:  

Keywords:  Neutralisation; Pseudotyped virus; SARS-CoV; SARS-CoV-2; Tropism

Year:  2021        PMID: 34859135      PMCID: PMC8595443          DOI: 10.21769/BioProtoc.4249

Source DB:  PubMed          Journal:  Bio Protoc        ISSN: 2331-8325


  18 in total

1.  VSV-G pseudotyped lentiviral vector particles produced in human cells are inactivated by human serum.

Authors:  N J DePolo; J D Reed; P L Sheridan; K Townsend; S L Sauter; D J Jolly; T W Dubensky
Journal:  Mol Ther       Date:  2000-09       Impact factor: 11.454

2.  EphrinB2 is the entry receptor for Nipah virus, an emergent deadly paramyxovirus.

Authors:  Oscar A Negrete; Ernest L Levroney; Hector C Aguilar; Andrea Bertolotti-Ciarlet; Ronen Nazarian; Sara Tajyar; Benhur Lee
Journal:  Nature       Date:  2005-07-06       Impact factor: 49.962

3.  Ross River virus glycoprotein-pseudotyped retroviruses and stable cell lines for their production.

Authors:  C M Sharkey; C L North; R J Kuhn; D A Sanders
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

4.  Characterization of Ebola virus entry by using pseudotyped viruses: identification of receptor-deficient cell lines.

Authors:  R J Wool-Lewis; P Bates
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

5.  DC-SIGN and DC-SIGNR bind ebola glycoproteins and enhance infection of macrophages and endothelial cells.

Authors:  Graham Simmons; Jacqueline D Reeves; Case C Grogan; Luk H Vandenberghe; Frédéric Baribaud; J Charles Whitbeck; Emily Burke; Michael J Buchmeier; Elizabeth J Soilleux; James L Riley; Robert W Doms; Paul Bates; Stefan Pöhlmann
Journal:  Virology       Date:  2003-01-05       Impact factor: 3.616

6.  Pseudotype Neutralization Assays: From Laboratory Bench to Data Analysis.

Authors:  Francesca Ferrara; Nigel Temperton
Journal:  Methods Protoc       Date:  2018-01-22

7.  An optimised method for the production of MERS-CoV spike expressing viral pseudotypes.

Authors:  K Grehan; F Ferrara; N Temperton
Journal:  MethodsX       Date:  2015-10-13

8.  Efficient generation of vesicular stomatitis virus (VSV)-pseudotypes bearing morbilliviral glycoproteins and their use in quantifying virus neutralising antibodies.

Authors:  Nicola Logan; Elizabeth McMonagle; Angharad A Drew; Emi Takahashi; Michael McDonald; Michael D Baron; Martin Gilbert; Sarah Cleaveland; Daniel T Haydon; Margaret J Hosie; Brian J Willett
Journal:  Vaccine       Date:  2015-12-17       Impact factor: 3.641

9.  Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19.

Authors:  Rebecca K McLean; Alexandra J Spencer; Tobias J Tuthill; Teresa Lambe; Simon P Graham; Sandra Belij-Rammerstorfer; Daniel Wright; Marta Ulaszewska; Jane C Edwards; Jack W P Hayes; Veronica Martini; Nazia Thakur; Carina Conceicao; Isabelle Dietrich; Holly Shelton; Ryan Waters; Anna Ludi; Ginette Wilsden; Clare Browning; Dagmara Bialy; Sushant Bhat; Phoebe Stevenson-Leggett; Philippa Hollinghurst; Ciaran Gilbride; David Pulido; Katy Moffat; Hannah Sharpe; Elizabeth Allen; Valerie Mioulet; Chris Chiu; Joseph Newman; Amin S Asfor; Alison Burman; Sylvia Crossley; Jiandong Huo; Raymond J Owens; Miles Carroll; John A Hammond; Elma Tchilian; Dalan Bailey; Bryan Charleston; Sarah C Gilbert
Journal:  NPJ Vaccines       Date:  2020-07-27       Impact factor: 7.344

10.  ChAdOx1 nCoV-19 protection against SARS-CoV-2 in rhesus macaque and ferret challenge models.

Authors:  Teresa Lambe; Alexandra J Spencer; Kelly M Thomas; Karen E Gooch; Stephen Thomas; Andrew D White; Holly E Humphries; Daniel Wright; Sandra Belij-Rammerstorfer; Nazia Thakur; Carina Conceicao; Robert Watson; Leonie Alden; Lauren Allen; Marilyn Aram; Kevin R Bewley; Emily Brunt; Phillip Brown; Breeze E Cavell; Rebecca Cobb; Susan A Fotheringham; Ciaran Gilbride; Debbie J Harris; Catherine M K Ho; Laura Hunter; Chelsea L Kennard; Stephanie Leung; Vanessa Lucas; Didier Ngabo; Kathryn A Ryan; Hannah Sharpe; Charlotte Sarfas; Laura Sibley; Gillian S Slack; Marta Ulaszewska; Nadina Wand; Nathan R Wiblin; Fergus V Gleeson; Dalan Bailey; Sally Sharpe; Sue Charlton; Francisco J Salguero; Miles W Carroll; Sarah C Gilbert
Journal:  Commun Biol       Date:  2021-07-26
View more
  5 in total

1.  Efficacy of ChAdOx1 vaccines against SARS-CoV-2 Variants of Concern Beta, Delta and Omicron in the Syrian hamster model.

Authors:  Neeltje van Doremalen; Jonathan E Schulz; Danielle R Adney; Taylor A Saturday; Robert J Fischer; Claude Kwe Yinda; Nazia Thakur; Joseph Newman; Marta Ulaszewska; Sandra Belij-Rammerstorfer; Greg Saturday; Alexandra J Spencer; Dalan Bailey; Sarah C Gilbert; Teresa Lambe; Vincent J Munster
Journal:  Res Sq       Date:  2022-02-15

2.  Evaluation of electropolymerized molecularly imprinted polymers (E-MIPs) on disposable electrodes for detection of SARS-CoV-2 in saliva.

Authors:  H F El Sharif; S R Dennison; M Tully; S Crossley; W Mwangi; D Bailey; S P Graham; S M Reddy
Journal:  Anal Chim Acta       Date:  2022-04-01       Impact factor: 6.911

3.  Porcine Respiratory Coronavirus as a Model for Acute Respiratory Coronavirus Disease.

Authors:  Sarah Keep; Brigid Veronica Carr; Fabian Z X Lean; Albert Fones; Joseph Newman; Giulia Dowgier; Graham Freimanis; Eleni Vatzia; Noemi Polo; Holly Everest; Isobel Webb; Adam Mcnee; Basu Paudyal; Nazia Thakur; Alejandro Nunez; Ronan MacLoughlin; Helena Maier; John Hammond; Dalan Bailey; Ryan Waters; Bryan Charleston; Toby Tuthill; Paul Britton; Erica Bickerton; Elma Tchilian
Journal:  Front Immunol       Date:  2022-03-28       Impact factor: 7.561

4.  ChAdOx1 nCoV-19 (AZD1222) or nCoV-19-Beta (AZD2816) protect Syrian hamsters against Beta Delta and Omicron variants.

Authors:  Neeltje van Doremalen; Jonathan E Schulz; Danielle R Adney; Taylor A Saturday; Robert J Fischer; Claude Kwe Yinda; Nazia Thakur; Joseph Newman; Marta Ulaszewska; Sandra Belij-Rammerstorfer; Greg Saturday; Alexandra J Spencer; Dalan Bailey; Colin A Russell; Sarah C Gilbert; Teresa Lambe; Vincent J Munster
Journal:  Nat Commun       Date:  2022-08-08       Impact factor: 17.694

5.  A platform technology for generating subunit vaccines against diverse viral pathogens.

Authors:  Andrew Young; Ariel Isaacs; Connor A P Scott; Naphak Modhiran; Christopher L D McMillan; Stacey T M Cheung; Jennifer Barr; Glenn Marsh; Nazia Thakur; Dalan Bailey; Kenneth S M Li; Hayes K H Luk; Kin-Hang Kok; Susanna K P Lau; Patrick C Y Woo; Wakako Furuyama; Andrea Marzi; Paul R Young; Keith J Chappell; Daniel Watterson
Journal:  Front Immunol       Date:  2022-08-18       Impact factor: 8.786

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.